Tuberin IHC Intensity

Whole-Exome Sequencing
Tumor DNA was isolated from formalin-fixed paraffin-embedded tissue with the DNeasy Blood & Tissue Kit (QIAGEN) using selected areas representative of the tumor. Germline DNA was isolated from peripheral blood using the FlexiGene DNA Kit (QIAGEN). Whole-exome sequencing (WES) was performed on DNA isolated from the primary tumor, a metastatic lesion, and from peripheral blood by the Centro de Análisis Genómico (CNAG), as described previously. 1 Briefly, exome capture was performed with the SureSelectXT Human All Exon V5 kit (Agilent Technologies) followed by massively parallel sequencing using 100-base pair paired-end technology on an Illumina HiSeq instrument. Mean depth of coverage was >90x. Sequencing data was analyzed to identify single nucleotide variants and small insertions or deletions as previously described. 1 An allele frequency threshold of 0.10 was applied. Variants were manually curated and candidate variants were validated by PCR followed by Sanger sequencing. The project was approved by the Instituto de Salud Carlos III (ISCIII) Review Board, the patient provided written informed consent to participate in the study, and all experiments were performed in accordance with relevant guidelines and regulations.
